ArticleLiver international : official journal of the International Association for the Study of the Liver2025
CD44 in Group 1 Innate Lymphoid Cells Impacts the Development and Progression of Steatohepatitis.
Article in Liver international : official journal of the International Association for the Study of the Liver, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Immune Determinants of MASLD Progression: From Immunometabolic Reprogramming to Fibrotic Transformation.Biology · 2026Review
- Microelements and biochemical biomarkers-based machine learning for predicting adverse pregnancy outcomes in Wilson's disease: risk stratification by integrating hepatic fibrosis and cerebral function.Frontiers in nutrition · 2026Article
- CD44 in Group 1 Innate Lymphoid Cells Impacts the Development and Progression of Steatohepatitis.Liver international : official journal of the International Association for the Study of the Liver · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors.
Funding
Abstract
BACKGROUND AND
aimsInnate lymphoid cells (ILCs) play pivotal roles in inflammation and fibrosis, which are key features of chronic liver diseases. The contribution of group 1 ILCs, including natural killer (NK) cells and helper-like ILC1s, to liver inflammation during steatohepatitis and metabolic dysfunction-associated steatotic liver diseases (MASLD) is still a matter of debate and requires further investigation.
methodsWe engineered a mouse model of specific deficiency of CD44 in group 1 ILCs and challenged mice with diet-induced obesity and MASLD or diet-induced steatohepatitis. We performed in vitro studies and co-cultured LPS-stimulated liver NK cells with hepatocytes and macrophages to analyse the inflammatory response.
resultsAs group 1 ILCs expressed the cell surface molecule CD44, its specific targeting was used to investigate if CD44 could affect the development of liver inflammation. Here, we found that CD44 deficiency in group 1 ILCs was sufficient to decrease the absolute number of hepatic NKp46
conclusionsOur findings reveal a novel role for CD44 in regulating the dynamics of group 1 ILCs, which in turn affects steatohepatitis and MASLD development.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.